Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInventory AverageInvested CapitalMarket Capitalization

RedHill Biopharma (RDHL) Net Margin: 2012-2023

Historic Net Margin for RedHill Biopharma (RDHL) over the last 11 years, with Jun 2023 value amounting to 3,280.68%.

  • RedHill Biopharma's Net Margin rose 352580.00% to 3,280.68% in Q2 2023 from the same period last year, while for Jun 2023 it was -111.91%, marking a year-over-year increase of 10647.00%. This contributed to the annual value of -102.80% for FY2024, which is 46905.00% down from last year.
  • RedHill Biopharma's Net Margin amounted to 3,280.68% in Q2 2023, which was up 1,590.99% from -220.03% recorded in Q1 2023.
  • RedHill Biopharma's 5-year Net Margin high stood at 3,280.68% for Q2 2023, and its period low was -658.08% during Q4 2021.
  • In the last 3 years, RedHill Biopharma's Net Margin had a median value of -30.18% in 2021 and averaged 181.24%.
  • As far as peak fluctuations go, RedHill Biopharma's Net Margin tumbled by 149,215bps in 2021, and later spiked by 352,580bps in 2023.
  • Quarterly analysis of 5 years shows RedHill Biopharma's Net Margin stood at 744.47% in 2019, then slumped by 65,273bps to 91.74% in 2020, then crashed by 74,982bps to -658.08% in 2021, then soared by 11,486bps to -543.22% in 2022, then soared by 352,580bps to 3,280.68% in 2023.
  • Its last three reported values are 3,280.68% in Q2 2023, -220.03% for Q1 2023, and -543.22% during Q4 2022.